The transfer of KRAS-reactive TCR-engineered T cells that recognize multiple HLA-A*11:01+ tumors has been shown to significantly induce tumor regression in immunized HLA-A*11:01 transgenic mice [39]. The gene discussed is KRAS; the disease is neoplasm.